Clinical Report: Validation of Shortened Versions of the HCL-32 for Bipolar Disorder
Overview
This study validates three abbreviated versions of the Hypomania Checklist (HCL-32) in an Arabic-speaking population, demonstrating strong reliability and good screening performance for differentiating bipolar disorder (BD) from major depressive disorder (MDD). The HCL-16 emerged as the most effective tool for identifying BD-II cases.
Background
Bipolar disorder is often misdiagnosed, with many patients initially diagnosed with major depressive disorder, leading to delayed treatment and poorer outcomes. Accurate screening tools are essential for early identification and management of bipolar disorder, particularly in populations where cultural factors may influence symptom reporting. The development of shorter, validated screening instruments can enhance the feasibility of identifying bipolar disorder in clinical settings.
All shortened HCL versions demonstrated strong reliability (α=0.78-0.90).
The AUC for the HCL-20 and HCL-16 indicated good screening ability (0.8520-0.8835).
Sensitivity for detecting BD-II was consistently higher than for BD-I across all scales.
The HCL-16 was identified as the most optimal scale for distinguishing BD from MDD.
This study represents the first validation of shortened HCL versions in an Arabic-speaking population.
Clinical Implications
The validated shorter versions of the HCL-32 can facilitate quicker and more efficient screening for bipolar disorder in clinical settings, particularly for BD-II, which is often under-recognized. Clinicians should consider incorporating these tools into their assessment protocols to improve diagnostic accuracy and treatment outcomes.
Conclusion
The validation of the HCL-20, HCL-16, and HCL-8 provides valuable tools for clinicians to enhance the identification of bipolar disorder in Arabic-speaking populations. The HCL-16, in particular, offers a balance of brevity and accuracy for effective screening.
